AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination With Chemotherapy in Patients With Relapsed/Refractory Leukemias Harboring Alterations in KMT2A/MLL, Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Etoposide (Primary) ; Fludarabine (Primary) ; Pegaspargase (Primary) ; Prednisone (Primary) ; Revumenib (Primary) ; Vincristine (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms AUGMENT-102
- Sponsors Syndax Pharmaceuticals
- 13 Aug 2024 Status changed from active, no longer recruiting to completed.
- 12 Jul 2024 Planned End Date changed from 1 Jun 2024 to 1 Jul 2024.
- 12 Jul 2024 Planned primary completion date changed from 1 May 2024 to 1 Jul 2024.